Alkermes plc - Ordinary Shares (ALKS)
31.33
-0.14 (-0.44%)
Alkermes Plc is a biopharmaceutical company focused on developing innovative treatments for people suffering from neurological and psychiatric disorders, as well as addiction
The company leverages its proprietary technologies and drug delivery systems to create medicines that address complex medical needs. With a commitment to advancing science and improving patient outcomes, Alkermes engages in the research, development, and commercialization of therapies that aim to enhance the quality of life for individuals dealing with serious health challenges.
![](https://www.chartmill.com/images/uploads/Undervalued_500_264px_webp_74997b3ff2.webp)
When you look at ALKERMES PLC (NASDAQALKS), it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
Via Chartmill · January 22, 2025
![](https://www.chartmill.com/images/uploads/Undervalued_500_264px_webp_74997b3ff2.webp)
ALKERMES PLC (NASDAQALKS) appears to be flying under the radar despite its strong fundamentals.
Via Chartmill · December 31, 2024
![](https://www.chartmill.com/images/uploads/Undervalued_500_264px_webp_74997b3ff2.webp)
ALKERMES PLC (NASDAQALKS): good value for what you're paying.
Via Chartmill · December 10, 2024
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · November 19, 2024
![](https://www.chartmill.com/images/uploads/Undervalued_500_264px_webp_74997b3ff2.webp)
Investors should take notice ofALKERMES PLC (NASDAQALKS)—it offers a great deal for the fundamentals it presents.
Via Chartmill · November 18, 2024
![](https://cdn.benzinga.com/files/images/story/2024/11/05/Stock-market-analysts.png?width=1200&height=800&fit=crop)
Via Benzinga · November 5, 2024
![](https://cdn.benzinga.com/files/images/story/2023/analyst_ratings_image_1.png?width=1200&height=800&fit=crop)
Via Benzinga · November 5, 2024
![](https://www.chartmill.com/images/uploads/Undervalued_500_264px_webp_74997b3ff2.webp)
ALKERMES PLC (NASDAQALKS), an undervalued stock with good fundamentals.
Via Chartmill · October 28, 2024
![](https://www.investors.com/wp-content/uploads/2017/05/IRU6.jpg)
Alkermes develops treatments for neurodegenerative diseases (conditions that damage and destroy parts of the nervous system) and cancer.
Via Investor's Business Daily · October 14, 2024
![](https://www.chartmill.com/images/uploads/Undervalued_500_264px_webp_74997b3ff2.webp)
ALKERMES PLC (NASDAQALKS) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
Via Chartmill · October 4, 2024
![](https://cdn.benzinga.com/files/images/story/2023/analyst_ratings_image_3.png?width=1200&height=800&fit=crop)
Via Benzinga · September 16, 2024
![](https://www.chartmill.com/images/uploads/Undervalued_500_264px_webp_74997b3ff2.webp)
For those who appreciate value investing, ALKERMES PLC (NASDAQALKS) is a compelling option with its solid fundamentals.
Via Chartmill · September 13, 2024
![](https://www.chartmill.com/images/uploads/Undervalued_500_264px_webp_74997b3ff2.webp)
For those who appreciate value investing, ALKERMES PLC (NASDAQALKS) is a compelling option with its solid fundamentals.
Via Chartmill · August 23, 2024
![](https://www.chartmill.com/images/uploads/Undervalued_500_264px_webp_74997b3ff2.webp)
Investors should take notice ofALKERMES PLC (NASDAQALKS)—it offers a great deal for the fundamentals it presents.
Via Chartmill · August 2, 2024
![](https://cdn.benzinga.com/files/images/story/2024/07/24/xrdDAFhS-kD63I2-j45998648077-t23042711_0.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · July 24, 2024
![](https://investorplace.com/wp-content/uploads/2022/05/earnings-season-1600.png)
ALKS stock results show that Alkermes beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via InvestorPlace · July 24, 2024
![](https://cdn.benzinga.com/files/images/story/2024/07/24/ATT-ATT.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · July 24, 2024
![](https://g.foolcdn.com/editorial/images/783372/july.jpeg)
Looking back at 30 five-stock samplers picked from 2015 to 2021.
Via The Motley Fool · July 15, 2024
![](https://www.chartmill.com/images/uploads/Undervalued_500_264px_webp_74997b3ff2.webp)
Investors should take notice ofALKERMES PLC (NASDAQALKS)—it offers a great deal for the fundamentals it presents.
Via Chartmill · July 11, 2024
![](https://www.chartmill.com/images/uploads/Undervalued_500_264px_webp_74997b3ff2.webp)
Don't overlook ALKERMES PLC (NASDAQALKS)—it's a hidden gem with strong fundamentals and an attractive price tag.
Via Chartmill · June 19, 2024
![](https://www.chartmill.com/images/uploads/Undervalued_500_264px_webp_74997b3ff2.webp)
Don't overlook ALKERMES PLC (NASDAQALKS)—it's a hidden gem with strong fundamentals and an attractive price tag.
Via Chartmill · May 29, 2024